The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis
Abstract
The diagnosis of an underlying chronic myeloproliferative disorder (CMPD) is often problematic in patients with primary extrahepatic portal vein obstruction (EHPVO) or Budd-Chiari syndrome (BCS); indeed, conventional clinical and hematological parameters usually yield insufficient information. To assess the diagnostic contribution of the gain-of-function mutation V617F of the JAK2 gene, 93 patients with EHPVO or BCS were investigated. JAK2 V617F was identified in 35.6% of 73 patients with EHPVO and in 40% of 20 patients with BCS. Taking the JAK2 mutation as a test with the highest positive predictive value for the diagnosis of CMPD, conventional clinical-hematological parameters had a sensitivity for CMPD lower than 48%. Bone marrow (BM) histology provided a diagnosis of CMPD in 41/74 (55.4%) patients, with a sensitivity of 93.5%. Clonality of hematopoiesis as assessed by granulocyte X-chromosome inactivation was present in 65.1% of 43 informative female patients, with a sensitivity of 86.6%. By resolving the sensitivity bias of the JAK2 mutation with the results of BM histology and clonality assay, CMPD was diagnosed in 53% of patients with EHPVO or BCS. In conclusion , CMPD is the major cause of primary EHPVO or BCS. JAK2 V617F is a very reliable and noninvasive molecular marker for CMPD and should be used as a first test for diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
The World Health Organization (WHO) classification of the myeloid neoplasms
Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,197
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, A. V. (2005) · Blood · doi:10.1182/blood-2005-03-1320 · Cited by 843 · cited 2×
“2) Median platelet count, 109/L (range) 255 (37-1400) 263 (40-1400) 253 (37-570) Median spleen diameter, cm (range) 16 (11-25) 16 (11-24) 15.”
European consensus on grading bone marrow fibrosis and assessment of cellularity.
Thiele, J., Kvasnicka, H. M., Facchetti, F., Franco, V., van der Walt, J. D., & Orazi, A. (2005) · PubMed · Cited by 762
Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors
Denninger, M.-H., Chaït, Y., Casadevall, N., Hillaire, S., Guillin, M.-C., Bezeaud, A., Erlinger, S., Briere, J., & Valla, D. (2000) · Hepatology · doi:10.1002/hep.510310307 · Cited by 686
Identification of an Acquired JAK2 Mutation in Polycythemia Vera
Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S. B., & Zhao, Z. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500138200 · Cited by 615
Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years
Policitemia*, G. I. S. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-9-199511010-00003 · Cited by 502
Cited by
Vascular disorders of the liver # †
DeLeve, L. D., Valla, D.-C., & Garcia-Tsao, G. (2009) · Hepatology · doi:10.1002/hep.22772 · Cited by 978
Etiology, Management, and Outcome of the Budd-Chiari Syndrome
Murad, S. D., Plessier, A., Hernandez-Guerra, M., Fabris, F., Eapen, C. E., Bahr, M. J., Trebicka, J., Morard, I., Lasser, L., Heller, J., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-3-200908040-00004 · Cited by 532
Self-citationSingal, A. K., Kamath, P. S., & Tefferi, A. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.012 · Cited by 389
Parikh, S., Shah, R., & Kapoor, P. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.05.023 · Cited by 270
Dentali, F., Squizzato, A., Brivio, L., Appio, L., Campiotti, L., Crowther, M., Grandi, A. M., & Ageno, W. (2009) · Blood · doi:10.1182/blood-2008-12-196014 · Cited by 176
Metadata
- Authors
- Primignani, M., Barosi, G., Bergamaschi, G., Gianelli, U., Fabris, F., Reati, R., Dell'Era, A., Bucciarelli, P., & Mannucci, P. M.
- Venue
- Hepatology
- Published
- 2006-12
- Volume
- 44
- Issue
- 6
- Pages
- 1528-1534
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1991452357
- Cited by
- 254
- References
- 26
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. https://app.cochat.ai/papers/10.1002/hep.21435
- The paper
- Primignani, M., Barosi, G., Bergamaschi, G., Gianelli, U., Fabris, F., Reati, R., Dell'Era, A., Bucciarelli, P., & Mannucci, P. M. (2006). Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. https://doi.org/10.1002/hep.21435
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
